- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01248793
Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis
March 14, 2013 updated by: Centocor, Inc.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Ankylosing Spondylitis
The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with ankylosing spondylitis
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Golimumab is a type of tumor necrosis factor (TNF) inhibitor.
TNF is a naturally occurring substance in the body, and this substance may cause long-term inflammation.
Golimumab may help fight disease by blocking the activity of TNF in the body and reducing inflammation and pain.
Each patient who is allowed to join the study will be put into a group randomly, like flipping a coin.
Patients may get either golimumab or placebo (which looks like the drug being studied but has no active ingredients, for example a sugar pill).
The chance that the patient will get golimumab is 1 to 1, so 50% chance to receive golimumab and 50% change to receive placebo.
Patients who do not have an improvement in total back pain and morning stiffness at the Week 16 visit compared to when the patients entered the study, and are in Group 1 (placebo group), will receive golimumab 50 mg every 4 weeks starting at Week 16.
If the patient is in Group 2 (golimumab 50 mg), they will continue to receive golimumab every 4 weeks starting at Week 16.
If the patient is in Group 1 and still receiving placebo injections, because there was improvement in total back pain at Week 16, they will receive golimumab 50 mg every 4 weeks starting from Week 24.
If the patient is in Group 2 (golimumab 50 mg) or are already receiving golimumab injections at week 24, they will continue to receive golimumab every 4 weeks.
Safety will be monitored throughout the study, including drawing blood and looking at laboratory tests, vital signs (eg, blood pressure), and the frequency and type of adverse events (side effects).
The patient will be in the study approximately 56 weeks.
Patients will receive placebo or active compound (golimumab 50 mg subcutaneous injections) every four weeks until Week 48.
Study Type
Interventional
Enrollment (Actual)
213
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
-
Chengdu, China
-
Guangzhou, China
-
Hefei, China
-
Jinan, China
-
Shanghai, China
-
Xi'An, China
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have a diagnosis of definite akylosing spondylitis for at least 3 months
- Have symptoms of active disease at screening and at baseline
- no active infections
Exclusion Criteria:
- Have other inflammatory diseases that might confound the evaluations of benefit from the golimumab therapy
- Have complete ankylosis of the spine
- Have a history of latent or active granulomatous infection
- Have had a serious infection, or have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 2 months prior to first administration of study agent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Golimumab
|
Golimumab 50 mg SC injection every 4 weeks for 48 weeks
|
Experimental: Placebo
|
Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 14
Time Frame: Week 14
|
Number of patients who achieved a >= 20% improvement in ankylosing spondylitis symptoms, including back pain, function, and inflammation
|
Week 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 24
Time Frame: Week 24
|
Number of patients who achieved a >= 20% improvement in ankylosing spondylitis symptoms, including back pain, function, and inflammation
|
Week 24
|
Change From Baseline in the Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14
Time Frame: Baseline and Week 14
|
BASFI is a participant's self-assessment, represented as a mean (Visual Analogue Scale [Score]; 0 cm [easy] to 10 cm [impossible]) of 10 questions, 8 of which relate to the participant's functional anatomy and 2 of which relate to a participant's ability to cope with everyday life.
A negative change from baseline indicates improvement.
|
Baseline and Week 14
|
Change From Baseline in the Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 14
Time Frame: Baseline and Week 14
|
BASMI is a combined score of 5 components of spine flexibility, ranging from 0 (least impairment) to 10 (most impairment).
A negative change from baseline indicates improvement.
|
Baseline and Week 14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
March 1, 2012
Study Registration Dates
First Submitted
November 24, 2010
First Submitted That Met QC Criteria
November 24, 2010
First Posted (Estimate)
November 25, 2010
Study Record Updates
Last Update Posted (Estimate)
March 20, 2013
Last Update Submitted That Met QC Criteria
March 14, 2013
Last Verified
March 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Joint Diseases
- Musculoskeletal Diseases
- Arthritis
- Spinal Diseases
- Bone Diseases
- Spondylarthropathies
- Bone Diseases, Infectious
- Ankylosis
- Spondylitis
- Spondylarthritis
- Spondylitis, Ankylosing
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tumor Necrosis Factor Inhibitors
- Antibodies, Monoclonal
- Golimumab
Other Study ID Numbers
- CR015916
- C0524T29 (Other Identifier: Centocor)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ankylosing Spondylitis
-
Shanghai Junshi Bioscience Co., Ltd.Sponsor GmbHRecruitingActive Ankylosing SpondylitisChina
-
AbbVieBoehringer IngelheimCompletedAnkylosing Spondylitis (AS)
-
Sun Yat-sen UniversityUnknownEarly Ankylosing Spondylitis
-
AbbVieCompletedAnkylosing Spondylitis (AS)United States, Australia, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Spain, Sweden, United Kingdom
-
AbbVieCompletedAnkylosing Spondylitis (AS)Taiwan
-
Tongji HospitalWuhan Central Hospital; Wuhan Hospital of Traditional Chinese MedicineRecruitingAnkylosing Spondylitis (AS)China
-
Chinese University of Hong KongCompletedAnkylosing Spondylitis(AS)China
-
Tianjin Hemay Pharmaceutical Co., LtdCompletedActive Ankylosing SpondylitisChina
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingActive Ankylosing SpondylitisChina
-
Ankara City Hospital BilkentRecruitingAxial Spondyloarthritis and Ankylosing SpondylitisTurkey
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States